Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 103.71% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 13.19% |
| 10 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 25.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.91% |
| Mar 31, 2026 | 37.30% |
| Dec 31, 2025 | 206.01% |
| Sep 30, 2025 | -2.55% |
| Jun 30, 2025 | 88.98% |
| Mar 31, 2025 | -51.02% |
| Dec 31, 2024 | -10.07% |
| Sep 30, 2024 | 18.86% |
| Jun 30, 2024 | -12.80% |
| Mar 31, 2024 | 281.79% |
| Dec 31, 2023 | -4.29% |
| Sep 30, 2023 | 38.41% |
| Jun 30, 2023 | -1.90% |
| Mar 31, 2023 | -61.58% |
| Dec 31, 2022 | -21.31% |
| Sep 30, 2022 | -31.79% |
| Jun 30, 2022 | -55.63% |
| Mar 31, 2022 | -23.37% |
| Dec 31, 2021 | 80.77% |
| Sep 30, 2021 | -26.85% |